Claudin18.2在实体瘤中的研究进展

Research progress of Claudin18.2 in solid tumors

针对恶性实体瘤,应用手术、放疗、化疗等治疗使患者生存率得到提高,但化疗药物具有选择性低、毒副作用大等缺点。通过研究,靶向药物的疗效展现出了良好的前景。Claudin(CLDN)18.2为不同恶性实体瘤的独特分子,针对CLDN18.2的靶向治疗是最具研究前景的热点。该文针对CLDN18.2的研究进展展开综述。

For malignant solid tumors,we use surgery,radiotherapy,chemotherapy,and other treatments to improve the patients'survival rate,but the application of chemotherapy drugs has the disadvantages of low selectivity and toxicity and side effects.Through research,the efficacy of targeted drugs has shown good prospects.Claudin18.2 is a unique molecule for different malignant solid tumors,and targeted therapy for Claudin18.2 is the most promising research hotspot.This study reviews the research progress of Claudin18.2.